CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Share Repurchase Programs Total Shareholders' Equity Attributable to Bruker Corporation	Share Repurchase Programs Common Stock	Share Repurchase Programs Treasury Stock	Share Repurchase Programs	Other Treasury Stock Acquired Total Shareholders' Equity Attributable to Bruker Corporation	Other Treasury Stock Acquired Common Stock	Other Treasury Stock Acquired Treasury Stock	Other Treasury Stock Acquired	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income	Noncontrolling Interests in Consolidated Subsidiaries	Total
Balance at beginning of period at Dec. 31, 2015									$ 726.1	$ 1.7	$ (90.9)	$ 102.1	$ 757.4	$ (44.2)	$ 6.8	$ 732.9
Balance (in shares) at Dec. 31, 2015										165,354,180	4,290,527
Increase (Decrease) in Stockholders' Equity
Restricted shares issued (in shares)										13,105
Restricted shares terminated (in shares)										(1,375)	1,375
Stock options exercised									12.0			12.0				12.0
Stock options exercised (in shares)										895,078
Stock based compensation									9.4			9.4				9.4
Excess tax benefit related to exercise of stock awards									1.3			1.3				1.3
Shares issued for acquisition									2.0		$ 2.1	(0.1)				2.0
Shares issued for acquisition (in shares)										90,066	(90,066)
Shares repurchased and treasury stock acquired	$ (160.0)		$ (160.0)	$ (160.0)	$ (0.5)		$ (0.5)	$ (0.5)
Shares repurchased and treasury stock acquired (in shares)		(6,475,480)	6,475,480,000,000			(20,879)	20,879
Distributions to noncontrolling interests															(0.7)	(0.7)
Cash dividends paid to common stockholders									(25.8)				(25.8)			(25.8)
Consolidated net income									153.6				153.6		0.9	154.5
Other comprehensive income (loss)									(31.7)					(31.7)	(0.3)	(32.0)
Balance at end of period at Dec. 31, 2016									686.4	$ 1.7	$ (249.3)	124.7	885.2	(75.9)	6.7	693.1
Balance (in shares) at Dec. 31, 2016										159,854,695	10,698,195
Increase (Decrease) in Stockholders' Equity
Restricted shares issued (in shares)											4,053
Restricted shares terminated (in shares)										(4,053)
Stock options exercised									20.4			20.4				20.4
Stock options exercised (in shares)										1,263,767
Restricted stock units vested									(0.3)			(0.3)				(0.3)
Restricted stock units vested (in shares)										58,419
Stock based compensation									11.0			11.0				11.0
Excess tax benefit related to exercise of stock awards									3.6				3.6			3.6
Shares issued for acquisition									0.6		$ 0.5	0.1				0.6
Shares issued for acquisition (in shares)										18,110	(18,110)
Shares repurchased and treasury stock acquired	$ (152.2)		$ (152.2)	$ (152.2)	$ (0.2)		$ (0.2)	$ (0.2)
Shares repurchased and treasury stock acquired (in shares)		(5,318,063)	5,318,063			(6,898)	6,898
Distributions to noncontrolling interests															(1.0)	(1.0)
Cash dividends paid to common stockholders									(25.4)				(25.4)			(25.4)
Consolidated net income									78.6				78.6		1.7	80.3
Other comprehensive income (loss)									102.9					102.9	0.7	103.6
Balance at end of period at Dec. 31, 2017									725.4	$ 1.7	$ (401.2)	155.9	942.0	27.0	8.1	733.5
Balance (in shares) at Dec. 31, 2017										155,865,977	16,009,099
Increase (Decrease) in Stockholders' Equity
Restricted shares terminated (in shares)										(6,553)	6,553
Stock options exercised									10.3			10.3				10.3
Stock options exercised (in shares)										575,372
Restricted stock units vested									(0.6)			(0.6)				(0.6)
Restricted stock units vested (in shares)										183,772
Stock based compensation									11.3			11.3				11.3
Stock returned for acquisition									(0.1)		$ (0.1)					(0.1)
Shared returned for acquisition (in shares)										(2,123)	2,123
Shares repurchased and treasury stock acquired									(0.2)		$ (0.2)					(0.2)
Shares repurchased and treasury stock acquired (in shares)										(7,105)	7,105
Distributions to noncontrolling interests															(0.9)	(0.9)
Cash dividends paid to common stockholders									(25.1)				(25.1)			(25.1)
Adoption impact from new revenue standard | ASC 606									5.9				5.9		0.2	6.1
Consolidated net income									179.7				179.7		1.3	181.0
Other comprehensive income (loss)									(10.0)					(10.0)	(0.2)	(10.2)
Balance at end of period at Dec. 31, 2018									$ 896.6	$ 1.7	$ (401.5)	$ 176.9	$ 1,102.5	$ 17.0	$ 8.5	$ 905.1
Balance (in shares) at Dec. 31, 2018										156,609,340	16,024,880